Navigation Links
Champions Biotechnology, Inc. Signs Exclusive Licensing Agreement with Ramot for TAR-1, a Novel Therapeutic for the Treatment of Cancer
Date:10/27/2009

tive preclinical platform and tumor specific data to physicians for personalized patient care and to companies for evaluation of oncology drugs in models that integrate prognostic testing with biomarker discovery.

www.championsbiotechnology.com

www.personalizedcancertreatment.com

Ramot at Tel Aviv University Ltd.

Ramot at Tel Aviv University Ltd. is the technology transfer company of Tel Aviv University (TAU). Ramot fosters, initiates, leads and manages the transfer of new technologies from university laboratories to the marketplace by performing all activities relating to the protection and commercialization of inventions and discoveries made by faculty, students and other researchers. Ramot provides a dynamic interface connecting industry to leading edge science and innovation, offering new business opportunities in a wide variety of emerging markets. Founded in 1956, TAU is one of Israel's foremost research and teaching universities. Located in Israel's cultural, financial and industrial heartland, TAU is at the forefront of basic and applied research in a wide variety of scientific research disciplines.

www.ramot.org

This press release contains "forward-looking statements" (within the meaning of the Private Securities Litigation Act of 1995) that inherently involve risk and uncertainties. Champions Biotechnology generally uses words such as "believe," "may," "could," "will," "intend," "expect," "anticipate," "plan," and similar expressions to identify forward-looking statements. One should not place undue reliance on these forward-looking statements. The Company's actual results could differ materially from those anticipated in the forward-looking statements for many unforeseen factors. See Champions Biote
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. U.S. Patent Issued for Champions Biotechnologys Lead Oncology Drug
2. Champions Biotechnology Begins Preclinical Development of Its Lead Oncology Drug Candidate
3. Champions Biotechnology and Concordia Pharmaceuticals Complete Service Agreement and Begin Preclinical Evaluation of Oncology Drugs
4. Cephalon Signs Option Agreement to Acquire BioAssets Development Corporation
5. Wound Management Technologies (OTCBB- WNDM) Signs Biotech Agreement With Biocure S.r.l. of Milan, Italy
6. NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer
7. Cardiac Science Expands into Vital Signs Market with Exclusive OMRON Healthcare Agreement
8. Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in Peoples Republic of China
9. AccuVein Signs Multiple-Country Distribution Agreement in Europe for Vein Illumination Device
10. Transgenomic Signs Exclusive License for Cold-PCR Technology From the Dana-Farber Cancer Institute
11. Paratek Pharmaceuticals Signs Worldwide License and Commercialization Agreement for PTK 0796, Broad-Spectrum Oral and IV Antibiotic in Phase 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014  eRelevance Corporation ( ... announced today that it has completed integration with ... for Plastic Surgery and Dermatology practices. ... value to healthcare practices using Nextech," stated ... Corporation. "Using information from the EMR we are ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - Eisai Limited is ... introduction of the first-of-its-kind comic book available in ... has been designed specifically to educate children and their parents ... Canada affecting more than 300,000 Canadians. Eisai is ... care (hhc) , in which the patient is central – ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- Inc. magazine today ... third straight year, No. 349 in Health on ... of the nation,s fastest-growing private companies. The list ... important segment of the economy—America,s independent entrepreneurs. Companies ... LinkedIn, Zillow, and many other well-known names gained ...
Breaking Medicine Technology:eRelevance Corporation Integrates with Nextech Electronic Medical Records 2Eisai Pleased to Support Canadian Epilepsy Alliance Comic Book that Teaches Children About Epilepsy 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 2Carolina's HME Named for Third Straight Year to Inc. Magazine's List of America's Fastest-Growing Private Companies--the Inc. 5000 3
... 11, 2007 - New data,supporting the clinical development ... oral protease inhibitors for the,treatment of hepatitis C ... Annual Meeting of the European Association for the,Study ... In total, nine,abstracts related to telaprevir have been ...
... 11, 2007 /PRNewswire-FirstCall/ -- Vical,Incorporated today announced ... company's Vaxfectin(TM) adjuvant generated up,to 60-fold higher ... same dose in a recently completed study ... vaccine with,Vaxfectin(TM) also allowed a nearly 10-fold ...
Cached Medicine Technology:Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 2Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 3Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 4Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 5Vertex Pharmaceuticals Announces New Data for Investigational HCV,Protease Inhibitor Telaprevir to be Presented at 42nd Annual,Meeting of the European Association for the Study of the Liver,(EASL) 6Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 2Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 3Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 4Vical's Vaxfectin Adjuvant Achieves Dose-Sparing Effect With,Seasonal Influenza Vaccine 5
(Date:8/23/2014)... Cardiomyopathy (heart muscle disease) is ... myocardium (the heart muscle) for any reason, usually ... (breathlessness) and peripheral edema (swelling of the legs). ... dangerous forms of irregular heart beat and sudden ... is dilated cardiomyopathy. , Clinical trial report, “Cardiomyopathy ...
(Date:8/23/2014)... 23, 2014 The report “Polycarbonate ... & Forecasts to 2018” defines and segments the ... of the global revenue and consumption. It also ... polycarbonate resin market with analysis of trends, opportunities, ... and consumption and revenues are forecasted on the ...
(Date:8/23/2014)... 2014 According to the new ... Application and Geography - Regional Trends & Forecast ... Market with an analysis and forecast of value ... of electronic adhesives by applications and geography are ... market data tables and 26 figures spread through ...
(Date:8/23/2014)... August 23, 2014 A team of New ... last longer when preceded by surgery and delivered by an ... the new study. Click here to read it now ... the cases of mesothelioma patients who underwent hemithoracic ... radiotherapy dose to the shape of a tumor. Patients ...
(Date:8/23/2014)... August 23, 2014 On Monday, August ... a data breach suffered by Community Health Systems, ... compromise of 4.5 million records containing Personally Identifiable Information ... According to Mandiant, who was engaged to investigate the ... an advanced group of cyber attackers based in China, ...
Breaking Medicine News(10 mins):Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 2Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 3Health News:Cardiomyopathy (Heart Muscle Disease) Therapeutics Clinical Trials Market 2014 Analysis in a New Report Available at MarketOptimizer.org 4Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 2Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 3Health News:Polycarbonate Resin Market by Applications and Geography Projected to $18.3 Billion by 2018 - New Report by MarketsandMarkets 4Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 2Health News:Electronic Adhesives Market Poised to Reach $5.5 Billion by 2019 - New Report by MarketsandMarkets 3Health News:New Study Links Hospital Experience and Prior Surgery with Mesothelioma Radiation Success, According to Surviving Mesothelioma 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4
... Reports’ has just enabled some valuable advice about chicken, which ... From virus to bacteria//, chicken seems to be hounded incessantly ... of 525 chickens, it found that nearly 83% of the ... or both. The bacteria are known to trigger diarrhea, cramping, ...
... study conducted by Asher Chanan-Khan, MD, Department of Medicine, ... for relapsed chronic lymphocytic leukemia (CLL) or diseases that ... response to the therapy. The results of this study ... Journal of Clinical Oncology. ,"Chronic lymphocytic ...
... a global initiative to develop a vaccine against malaria,// the ... ,The objective for the ‘Malaria Vaccine Technology Roadmap’ is ... fight Malaria by the year 2015. ,Malaria ... and rightly it is one of the oldest diseases in ...
... The popular hair-growth drug finasteride, taken by millions of ... antigen (PSA) test,// the standard screening test for prostate ... involving 308 men ranging in age from 40 to ... medical journal The Lancet and is scheduled to be ...
... was the focus of attention following an E. coli outbreak. ... with abdominal cramps, //fever and diarrhea. They were diagnosed with ... restaurants, operated by Yum Brands Inc in New Jersey have ... of the sick people reported that they had eaten from ...
... under Section 5 of the Insecticides Act, 1968 registers ... safety.// Toxicity and residues data generated under supervised trials ... (MRLs) by the Ministry of Health & Family Welfare ... Rules framed thereunder. The inspection of fruits and vegetables ...
Cached Medicine News:Health News:Hair-Growth Drug Artificially Lowers Psa Levels in Prostate Cancer Screening 2
Angled shaft with 0.2 tip, round serrated handle, dull finish, overall length 130 mm...
... simplus multi-action solution is the first and ... only cleans, disinfects and conditions gas permeable ... with cleaning comparable to the leading two-bottle ... system provides comfort upon insertion by enveloping ...
Menicon Z is a rigid gas lens with high oxygen permeability. As one of its specific characteristics, it can provide superior visual correction and show excellent performance against astigmatism....
... using sophisticated lathing techniques, intrinsically permeable polymers ... a center thickness of just 0.08 across ... powered Thinsite lenses maintain a 30% decrease ... unique design eliminates stress points to reduce ...
Medicine Products: